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Aim of study
Prostate cancer (PCa) ranks third in cancer incidence and
is the fourth leading cause of cancer-related deaths in
Italy. The widespread use of the PSA test in clinical prac-
tice has been associated with a constant increase in the
number of diagnosed PCa cases both in the USA (170 per
100,000) and Europe. In Italy the rate rose from 20 cases
per 100,000 in 1976 to 40 per 100,000 in 1997.
Materials and methods
We performed in "Dipartimento di Scienze Chirurgiche,
Trapianti d'Organo e Tecnologie Avanzate", Università di
Catania in the last five years, 96 prostatic mapping in
patients (over 80 years old). All patients presented a Pros-
tatic Specific Antigen level (PSA) over 2.5 ng/ml. In
patients with PSA rate under 10 ng/ml and with E.D.A.R.
or negative transanal US, dosage PSA free/tot. was lower
than 15 per cent.
45 patients constituted this group, aged between 80 and
88 years old. We performed all prostatic mapping by local
anesthesia using a 18 GG needle.
Results
This method permits to demonstrate a positive diagnosis
for cancer in 27 patients (60%); other patients underwent
to another prostatic mapping after an year because of high
PSA level (18 prostatic mapping, just a case positive for
cancer). Other three follow-up patients, demonstrated a
high PSA level higher than 0.5 ng/ml. Prostatic mapping
(12 biopsy) allowed us to confirm a recurrence neoplasm.
Conclusion
This reduction in the PCa mortality rate, which has coin-
cided with the widespread use of the PSA test, is to be
attributed to the higher number of organ-confined (and
therefore curable) cancers detected but also to a more
effective treatment of the advanced disease and to a more
accurate identification of causes of death; in fact, the areas
with the highest rates of early detection and treatment
(USA and Canada) do not report the lowest mortality
rates. The reduction in PCa mortality in Italy has been
noted in all the age groups where there had been the high-
est increase in the incidence of this cancer. Early diagnosis
of an increasing number of organ-confined cases and the
resulting intention-to-treat approach are likely to have
contributed to this outcome.
Early diagnosis, screening for this kind of cancer (PSA dos-
age and prostatic mapping), natural biological behavior
and evolution in medical and surgical treatment had
improved prognosis, life quality for patient who had diag-
nosed prostatic cancer.
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